Studies show that Q-actin reduced LPS-induced pro-inflammatory cytokine tumour necrosis factor alpha (TNFα) in both ex vivo human serum and THP-1 cells. TNFα can drive degenerative changes such as in joints when chronically elevated.  Research shows that ido-BR1 works in a dose-dependent manner to reduce inflammatory markers, including LPS-induced production of TNFα, IL-6, nitric oxide and the transcription factor NF-κB.

​

​

​

​